Santen Pharmaceutical Co., Ltd.
Q1 FY2027 IFRS Consolidated Financial Results for the First Quarter
Consolidated net sales for the first quarter of FY2027 were 68,957 million yen (up 0.3% YoY), core operating income was 10,605 million yen (up 9.3%), and net income attributable to owners of the parent was 7,199 million yen (up 22.8%), marking an increase in both revenue and profit. The full-year outlook remains unchanged. Treasury shares were increased among held shares, with a focus on improving ROE and ROIC.
Key Figures
- Net sales: 68,957百万円
- Core operating income: 10,605百万円
- Operating income: 8,116百万円
AI要約
Performance overview
In the first quarter of the current period, net sales reached 68,957 million yen despite expansion initiatives for new and core products, affected by drug price revisions. Core operating income grew by 9.3% as structural cost increases were absorbed, and IFRS operating profit contributed to the year-on-year increase. Quarterly profit and quarterly profit attributable to owners of the parent surged substantially. The full-year outlook remains unchanged from the time of disclosure, and dividend expectations are also maintained. The company aims to maximize ROE and ROIC and is taking steps to improve working capital efficiency.
Outlook and shareholder return
There is no change to the full-year forecast for FY2027, and the dividend outlook remains at the latest disclosed value. While statements regarding treasury stock acquisition/holding are included, there are no new specific buyback plans shown here. Going forward, the company intends to continue improving ROE/ROIC through new product market expansion and cost reductions, to maximize shareholder value.
Santen Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
